Melissa Johnson, MD

A panelist discusses how novel bispecifics and ADCs signal a more hopeful future for ES-SCLC management.

A panelist discusses how lurbinectedin and tarlatamab both remain essential options within evolving treatment strategies.

A panelist discusses how proactive management of CRS and ICANS supports safe community use of DLL3-targeted therapy.

A panelist discusses how tarlatamab’s strong efficacy data suggest a practice-changing advance for relapsed ES-SCLC.

A panelist discusses how early relapse and prognostic indicators shape second-line therapy selection and emerging treatment roles.

A panelist discusses how patient comorbidities and declining performance status drive individualized treatment planning in relapsed ES-SCLC.

Melissa Johnson, MD, associate director, Lung Cancer Research, Sarah Cannon Research Institute, discusses the use of natural language processing in the diagnosis of lung cancer.